Journal of neural transmission (Vienna, Austria : 1996)最新文献

{"title":"The spectrum of square wave jerks in essential tremor: an exploratory study.","authors":"Claudio Terravecchia, Roberta Terranova, Alessandra Rufa, Aasef G Shaikh, Clara Grazia Chisari, Andrea Salerno, Giulia Donzuso, Calogero Edoardo Cicero, Giovanni Mostile, Mario Zappia, Alessandra Nicoletti","doi":"10.1007/s00702-026-03134-y","DOIUrl":"10.1007/s00702-026-03134-y","url":null,"abstract":"","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":"2917-2924"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147477955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytokines and cognitive function in first-episode drug-naïve MDD: an inflammation panel perspective.","authors":"Yeqing Dong, Chuhao Zhang, Bin Zhang, Xue Tian, Ying Gao, Meijuan Li, Jie Li","doi":"10.1007/s00702-026-03133-z","DOIUrl":"10.1007/s00702-026-03133-z","url":null,"abstract":"<p><p>Inflammation is involved in the process of cognitive impairment in some psychiatric disorders; however, the relationship between cognitive function and inflammation markers in major depressive disorder (MDD) remains unclear. Herein, we sought to investigate the alterations in cytokine levels and the relationships between cytokine levels and cognitive performance in MDD patients and healthy controls (HCs) from the perspective of the inflammation panel. This present study included 170 participants, including 101 first-episode drug-naïve MDD patients and 69 HCs. The levels of 27 cytokines were assayed by the Bio-Plex human 27-plex (BioRad). The depressive and anxiety symptoms were evaluated using the Hamilton Depression Rating Scale-17 (HAMD-17) and Hamilton Anxiety Rating Scale-14 (HAMA-14), respectively. The cognitive function was assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Toronto Alexithymia Scale (TAS-20). First-episode drug-naïve MDD patients exhibited significantly poorer neurocognitive and social cognitive function compared to HCs, even after adjusting for potential confounders. Of the 27 cytokines measured, 26 were significantly elevated in MDD patients. The principal component analysis identified five components accounting for 71.26% of the variance, with four components differing significantly between the MDD and HC groups. Notably, PC3, comprising RANTES, IL-9, MIP-1beta, TNF-alpha, IL-2, and IL-10, demonstrated strong discriminative power between MDD and HCs (AUC = 0.829, 95%CI: 0.769-0.889). The analysis revealed that PC3 and its contained cytokines (RANTES, IL-9, IL-2, and IL-10) exhibited a negative correlation with the scores of TAS-20, RBANS, and its subscales in HCs, but no such associations were observed in MDD patients. Our findings may contribute to elucidating the biological mechanisms underlying cognitive impairment in MDD by emphasizing the relationship between cytokine subtypes, including RANTES, IL-9, IL-2, and IL-10, and cognitive functions.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":"2291-2300"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147392246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of COMT-inhibitors in parkinson's disease: a phase-IV comparative study on adverse events of Tolcapone, Entacapone and Opicapone.","authors":"Pasquale Maria Pecoraro, Simona Paola Carbone, Francesco Bugamelli, Lazzaro di Biase","doi":"10.1007/s00702-025-03053-4","DOIUrl":"10.1007/s00702-025-03053-4","url":null,"abstract":"<p><p>Catechol-O-methyltransferase (COMT) inhibitors-Tolcapone, Entacapone, and Opicapone-are adjunct therapies for advanced Parkinson's disease (PD), improving motor control. Their distinct safety profiles may influence clinical decisions and patient adherence. This study provides a comprehensive descriptive analysis of adverse events (AEs) reported for these drugs and a comparative safety assessment based on post-marketing AE reports and drug sales data from 2018 to 2023. A retrospective analysis was conducted using data from the FDA Adverse Event Reporting System (FAERS). AEs were categorized by severity and compared across COMT-inhibitors. Drug utilization trends were evaluated through retail and hospital sales data, expressed as standard units and market share. AE incidence was normalized for drug exposure using the median number of pills per day. Statistical comparisons were performed using Fisher's exact test to assess differences in AE rates. Entacapone was sold 100 times more than Opicapone and 1000 times more than Tolcapone. When normalized for drug exposure, total AEs were significantly lower for Entacapone than Opicapone (OR = 0.0435, p < 0.001) and Tolcapone (OR = 0.1397, p < 0.001). Tolcapone also exhibited a significantly lower AE risk than Opicapone (OR = 0.3119, p < 0.001). Similarly, Entacapone had significantly fewer serious AEs than Opicapone (OR = 0.0732, p < 0.001) and Tolcapone (OR = 0.0872, p < 0.001), indicating a more favorable safety profile. This is the first study directly comparing the safety profiles of COMT-inhibitors head-to-head. Entacapone appears to be the safest long-term COMT-inhibitor, with the lowest risk of both serious and non-serious AEs. A long-term, prospective clinical trial is warranted to overcome retrospective limitations and confirm these findings.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":"2891-2906"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Cytokines and cognitive function in first-episode drug-naïve MDD: an inflammation panel perspective.","authors":"Yeqing Dong, Chuhao Zhang, Bin Zhang, Xue Tian, Ying Gao, Meijuan Li, Jie Li","doi":"10.1007/s00702-026-03236-7","DOIUrl":"10.1007/s00702-026-03236-7","url":null,"abstract":"","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":"2301-2303"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148893318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferroptosis in depression: mechanisms, association, and therapeutic strategies.","authors":"Chu Zhang, Shuting Chen, Chuang Yan, Yingxu Jiang, Yuxiao Wang, Zhengfei Yu, Tian Xie, Meng Tian, Guangzhe Yao, Yiqi Yan, Zhidan Shi","doi":"10.1007/s00702-026-03248-3","DOIUrl":"10.1007/s00702-026-03248-3","url":null,"abstract":"<p><p>Depression is a highly disabling mental disorder, and the existing treatments have limitations. The development of new drugs is urgently needed. Ferroptosis, as a regulated form of cell death mediated by iron-dependent phospholipid peroxidation, is closely related to the pathological process of depression. In patients with depression and depression models, there are phenomena such as iron metabolism disorders, enhanced lipid peroxidation, and downregulation of anti-ferroptotic molecules like GPX4, etc. These processes involve the GPX4-GSH system, mitochondrial function, autophagy, etc., in the occurrence of the disease. Antioxidants targeting ferroptosis, iron chelators, and single or compound components of traditional Chinese medicine can improve depressive symptoms by inhibiting ferroptosis. This article reviews the mechanism of ferroptosis, its association with depression, and related treatment strategies, providing a new perspective for the study of depression mechanisms and drug development.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":"2153-2186"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148595361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic functional connectivity is related to cognitive performance of prodromal Lewy body dementia.","authors":"Martin Gajdoš, Marie Schejbalová, Martin Lamoš, Pavel Říha, Ľubomíra Nováková, Markéta Nečasová, Nela Němcová Elfmarková, Eva Výtvarová, Michal Mikl, Irena Rektorová","doi":"10.1007/s00702-026-03148-6","DOIUrl":"10.1007/s00702-026-03148-6","url":null,"abstract":"<p><p>Brain connectivity dynamics in mild cognitive impairment with Lewy bodies (MCI-LB) is largely unknown. We aimed to identify brain connectivity dynamics related to cognitive performance in drug naïve MCI-LB. Healthy (55 participants, age 67.7 ± 6.4, 33 females) and MCI-LB subjects (30 participants, age 68.5 ± 6.0, 16 females) underwent cognitive testing and fMRI. The fast eigenvector centrality dynamic functional connectivity was employed to detect connectivity states. Mean state duration and occurrence were correlated to cognitive measures. In the MCI-LB group only, the occurrence and mean duration of the state characterized by between-network connectivity of the dorsal attention, sensorimotor, and visual networks correlated with visuospatial function (VSF) domain z-scores (r = 0.68, p = 0.003, and r = -0.68, p = 0.003, respectively). The VSF also correlated with the occurrence of the state characterized by intra-network connectivity of the frontoparietal control network (r = -0.55, p = 0.041). We identified specific mechanisms that seem to facilitate visuospatial performance in MCI-LB.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":"2359-2369"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147583508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What can clinical disorders involving the basal ganglia tell us about the pathophysiology of obsessive and compulsive symptoms?","authors":"Violette Chereau, Benjamin R Underwood","doi":"10.1007/s00702-026-03226-9","DOIUrl":"10.1007/s00702-026-03226-9","url":null,"abstract":"<p><p>The neurobiology and pathological mechanisms underlying obsessive-compulsive symptoms have been explored in the literature for more than fifty years without reaching a definitive conclusion. What is clear is that some brain areas, including the basal ganglia and connected structures, have been implicated through several different approaches, including use of animal models and examination of human subjects with different cerebral lesions and pathologies. The purpose of this narrative review is to explore how examination of disorders affecting the basal ganglia can give insights into the pathophysiology of obsessive-compulsive symptoms and obsessive-compulsive disorder. These clinical conditions include Parkinson's disease, Huntington's disease, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), Sydenham's chorea, and Tourette's syndrome. We review neuroimaging, genetic, and clinical studies in these conditions. Overall, the literature discussed supports the idea that the reward circuitry, including the limbic and lateral orbitofrontal loops of the basal ganglia, as well as goal-directed versus habitual pathways in the dorsal striatum, are involved in obsessive-compulsive disorder and obsessive-compulsive symptoms.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":"2103-2120"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148671630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active electrode location does not influence weight gain after subthalamic nucleus deep brain stimulation surgery in Parkinson disease.","authors":"Amelia Heston, Asra Askari, Kara Wyant, Parag G Patil, Kelvin L Chou, Daniel Leventhal","doi":"10.1007/s00702-026-03201-4","DOIUrl":"10.1007/s00702-026-03201-4","url":null,"abstract":"<p><p>Weight change (WC) is a well-recognized and poorly understood side effect of deep brain stimulation (DBS). The aim of our study was to determine the relationship between active electrode location in the subthalamic nucleus (STN) and post-DBS WC. This was a single center retrospective study of 82 patients who underwent STN DBS. Two weeks after surgery, a head CT was obtained and co-registered to the patient's preoperative 3T MRI. The STN midpoint was identified, and the location of the active electrode was defined with respect to the STN midpoint in Talairach space. Least squares regression models were applied to evaluate the role of active electrode location on WC, as well as the relationships between WC and the explanatory variables sex, age, disease duration, change in levodopa equivalent dose (LED), change in MDS-UPDRS III scores, and change in dyskinesias before and after DBS. Active electrode contact location was not significantly associated with WC along any direction in either hemisphere. WC was significantly associated with change in dyskinesias (slope = -1.8 lbs/point, R² = 0.072, p = 0.025), but only in a univariate model. Our findings suggest that active electrode contact location does not influence WC after STN DBS.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":"2557-2566"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148255438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual rating scales of atrophy differentiate sporadic behavioral variant frontotemporal dementia from primary psychiatric disorder: DIPPA study.","authors":"Giorgio Giulio Fumagalli, Chiara Fornari, Sterre C M de Boer, Chiara Fenoglio, Andrea Arighi, Lina Riedl, Ramon Landin-Romero, Sophie Matis, Ishana Rue, Zac Chatterton, Janine Diehl-Schmid, Glenda Halliday, Simon Ducharme, Olivier Piguet, Daniela Galimberti, Yolande Pijnenburg","doi":"10.1007/s00702-026-03223-y","DOIUrl":"10.1007/s00702-026-03223-y","url":null,"abstract":"<p><p>Sporadic behavioral variant frontotemporal dementia (bvFTD) is often misdiagnosed as late-onset primary psychiatric disorder (PPD) due to overlapping symptoms and lack of disease-specific biomarkers. This multicenter pilot study aimed to identify brain atrophy patterns using visual rating scales (VRS) that distinguish between groups, and to compare VRS performance with standard clinical assessment. Magnetic resonance images from bvFTD and PPD patients across five centers were retrospectively reviewed. One rater, blinded for the clinical diagnosis, applied eight VRS. Group differences were assessed, the most predictive scales were identified and combined into a composite score, and the predictivity compared. 297 bvFTD and 92 PPD patients were analysed. All VRS yielded higher atrophy in bvFTD than in PPD patients. The Orbitofrontal, the Anterior-Temporal, and the Fronto-Insula scales were the strongest discriminators, and their composite score outperformed any individual scale. VRS may provide useful diagnostic support for distinguishing bvFTD from PPD.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":"2623-2634"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148371716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FBXO7- associated parkinsonism: clinical, genetic, and radiological insights from a case report and literature review.","authors":"Rohan R Mahale, Pramod Khanda, Subhajit Roy","doi":"10.1007/s00702-026-03221-0","DOIUrl":"10.1007/s00702-026-03221-0","url":null,"abstract":"<p><strong>Background: </strong>Variants in the FBXO7 gene are a recognized cause of juvenile-onset autosomal recessive parkinsonism (PARK15) with a heterogeneous phenotype. There is limited number of reported cases in the literature.</p><p><strong>Objective: </strong>To report a 19-year-old Indian man with juvenile-onset parkinsonism harbouring a novel FBXO7 variant and to review the published literature on FBXO7-associated parkinsonism/parkinsonism-pyramidal syndrome, focusing on the clinical, imaging, and genetic spectrum and possible genotype-phenotype correlations.</p><p><strong>Methods: </strong>We evaluated an Indian male with FBXO7-associated juvenile parkinsonism and reviewed previously published cases from the literature to assess the clinical, imaging, and genetic spectrum.</p><p><strong>Results: </strong>A total of 32 cases of FBXO7-associated parkinsonism, including our patient, were identified. The median age at onset was 17 years, median age at presentation was 28 years, with slight male predominance and a median disease duration of 5 years. Symmetrical juvenile-onset parkinsonism with tremor and postural instability was the commonest presentation. Dementia, dystonia, pyramidal signs, and gaze abnormalities were less frequent associated features. Most patients showed levodopa responsiveness, although motor complications and psychiatric adverse effects were common. Neuroimaging findings were heterogeneous, ranging from cortical atrophy to pallidal hypointensity and presynaptic dopaminergic deficits on dopamine transporter imaging. Twenty variants were identified, with the homozygous nonsense variant c.1492 C > T (p.Arg498*) being the most frequently reported.</p><p><strong>Conclusion: </strong>FBXO7-associated parkinsonism typically presents as symmetrical juvenile-onset levodopa-responsive parkinsonism, although early-onset parkinsonism is known. Dementia, dystonia, and pyramidal signs are less frequent associated features. FBXO7 variants should be considered in patients with symmetrical juvenile/early-onset parkinsonism, especially when accompanied by levodopa-induced psychiatric adverse effects.</p>","PeriodicalId":520679,"journal":{"name":"Journal of neural transmission (Vienna, Austria : 1996)","volume":" ","pages":"2599-2607"},"PeriodicalIF":4.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148348525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}